Benign prostatic hyperplasia affects about half of men between 51 and 60 years of age, and nine out of 10 men older than 80.

Benign prostatic hyperplasia affects about half of men between 51 and 60 years of age, and nine out of 10 men older than 80. 

that the 'leaked cytokines' promoted the recruitment of immune cells, especially macrophages and T cells, into the prostatic microenvironment


"Our results may explain why some BPH patients respond to androgen-targeting therapies, such as finasteride, while in other patients the disease continues to progress," said Xin. "We suggest that treatment for BPH might be more effective if patients received androgen-targeting therapy together with drugs that target inflammation."